Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2019. Module: SNOMED CT core
Descriptions:
Id | Description | Lang | Type | Status | Case? | Module |
3761868010 | Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
3761869019 | Lamivudine 150 mg and nevirapine 200 mg and stavudine 40 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Product manufactured as oral dose form (product) | false | Inferred relationship | Some | ||
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Product containing lamivudine and nevirapine and stavudine (medicinal product) | false | Inferred relationship | Some | ||
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Stavudine (substance) | false | Inferred relationship | Some | ||
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Lamivudine (substance) | false | Inferred relationship | Some | ||
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Nevirapine (substance) | false | Inferred relationship | Some | ||
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | Oral tablet | true | Inferred relationship | Some | ||
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Lamivudine- and nevirapine- and stavudine-containing product in oral dose form | false | Inferred relationship | Some | ||
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | Is a | TEMPORARY parent for CDs that are not updated | false | Inferred relationship | Some | ||
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the numerator unit for the presentation strength of a product. | mg | true | Inferred relationship | Some | 2 | |
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Product containing only lamivudine and nevirapine and stavudine in oral dose form (medicinal product form) | true | Inferred relationship | Some | ||
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the denominator unit for the presentation strength of a product. | Tablet (unit of presentation) | true | Inferred relationship | Some | 1 | |
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Stavudine (substance) | true | Inferred relationship | Some | 1 | |
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | 40 | false | Inferred relationship | Some | 1 | |
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the denominator unit for the presentation strength of a product. | Tablet (unit of presentation) | true | Inferred relationship | Some | 2 | |
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | Count of base of active ingredient | trois | false | Inferred relationship | Some | ||
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator value | un | false | Inferred relationship | Some | 2 | |
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator value | un | false | Inferred relationship | Some | 3 | |
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the numerator unit for the presentation strength of a product. | mg | true | Inferred relationship | Some | 1 | |
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator value | un | false | Inferred relationship | Some | 1 | |
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the numerator unit for the presentation strength of a product. | mg | true | Inferred relationship | Some | 3 | |
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Some | ||
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | This attribute specifies the denominator unit for the presentation strength of a product. | Tablet (unit of presentation) | true | Inferred relationship | Some | 3 | |
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Stavudine (substance) | true | Inferred relationship | Some | 1 | |
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Lamivudine (substance) | true | Inferred relationship | Some | 2 | |
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Lamivudine (substance) | true | Inferred relationship | Some | 2 | |
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. | Nevirapine (substance) | true | Inferred relationship | Some | 3 | |
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | 200 | false | Inferred relationship | Some | 3 | |
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | 150 | false | Inferred relationship | Some | 2 | |
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). | Nevirapine (substance) | true | Inferred relationship | Some | 3 | |
Product containing precisely lamivudine 150 milligram and nevirapine 200 milligram and stavudine 40 milligram/1 each conventional release oral tablet (clinical drug) | Plays role | Antiretroviral therapeutic role | false | Inferred relationship | Some |
Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets